
PBIGF
Healthcare · Biotechnology · $7.5M market cap
$0.01190.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.03 | — |
| Feb 22, 2021 | After the close | 0.00 | -0.03 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.04 | — |
| Aug 27, 2020 | After the close | 0.00 | -0.03 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.01 | — |
| Feb 13, 2020 | After the close | 0.00 | -0.01 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Aug 29, 2019 | After the close | 0.00 | -0.01 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.03 | — |
| Feb 20, 2019 | After the close | 0.00 | -0.03 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | -0.01 | — |
| Aug 23, 2018 | After the close | 0.00 | -0.01 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | -0.01 | — |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014…
| Mar 31, 2018 |
| Time not confirmed |
| 0.00 |
| -0.01 |
| — |